Quality of Life Assessed With the PAH SYMPACT Questionnaire

Mayo Clinic390 enrolled

Overview

Researchers are evaluating quality of life in pulmonary hypertension subjects using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire and assessing the questionnaires' performance with regard to relationship to other markers of disease severity, response to treatment, and outcome in a clinical practice setting.

Subjects will be recruited from among those seen at the Mayo Pulmonary Hypertension Clinic. The PAH-SYMPACT questionnaire will be administered either in written form or by telephone interview. On the second 100 patients implement a standardized palliative care referral program for patients with Group 1 and 3 PH and high SYMPACT scores\> 1.0.

Study Type

OBSERVATIONAL

Enrollment

390

Conditions

Pulmonary Hypertension

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or above * Consents to participate * Documented group I PAH based upon these hemodynamic criteria: (mPAP \> 20, PCW 18 or less, PVR \> 3 Wood units * Mean PAP \> 20, PCW ≤ 18, PVR \> 3 Wood units * Parenchymal lung disease that in the opinion of the investigator qualifies patient as group III PH * Documented chronic thromboembolic pulmonary hypertension or chronic thromboembolic disease with intent to treat with surgery, balloon pulmonary angioplasty, and/or PH medication Exclusion Criteria: * Left sided heart disease (LVEF\<50%, PAWP\>18) * Any other known concomitant life-threatening disease with a life expectancy \<12 months * Any other clinically relevant and/or serious chronic medical condition that would affect study participation in the opinion of the investigator * Non English speaking

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Quality of life in pulmonary hypertension subjects

Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe

Time frame: Baseline

Quality of life in pulmonary hypertension subjects

Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe

Time frame: 14 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.